These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8119066)

  • 1. Sample size requirements and length of study for testing interaction in a 2 x k factorial design when time-to-failure is the outcome [corrected].
    Peterson B; George SL
    Control Clin Trials; 1993 Dec; 14(6):511-22. PubMed ID: 8119066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 2 x 2 factorial design: its application to a randomized trial of aspirin and carotene in U.S. physicians.
    Stampfer MJ; Buring JE; Willett W; Rosner B; Eberlein K; Hennekens CH
    Stat Med; 1985; 4(2):111-6. PubMed ID: 4023472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A method of designing clinical trials for combination drugs.
    Pigeon JG; Copenhaver MD; Whipple JP
    Stat Med; 1992 Jun; 11(8):1065-74. PubMed ID: 1496194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of aspirin and beta-carotene among U.S. physicians.
    Hennekens CH; Eberlein K
    Prev Med; 1985 Mar; 14(2):165-8. PubMed ID: 3900975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reporting of randomized factorial trials was frequently inadequate.
    Kahan BC; Tsui M; Jairath V; Scott AM; Altman DG; Beller E; Elbourne D
    J Clin Epidemiol; 2020 Jan; 117():52-59. PubMed ID: 31585174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sample size requirements for comparing time-to-failure among k treatment groups.
    Makuch RW; Simon RM
    J Chronic Dis; 1982; 35(11):861-7. PubMed ID: 7142364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factorial designs: a graphical aid for choosing study designs accounting for interaction.
    Byth K; Gebski V
    Clin Trials; 2004; 1(3):315-25. PubMed ID: 16279257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and analysis of multiarm clinical trials with survival endpoints.
    Liu PY; Dahlberg S
    Control Clin Trials; 1995 Apr; 16(2):119-30. PubMed ID: 7789135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No reduction in cardiovascular risk with NSAIDs-including aspirin?
    Cleland JG
    Lancet; 2002 Jan; 359(9301):92-3. PubMed ID: 11809245
    [No Abstract]   [Full Text] [Related]  

  • 10. Factorial design considerations.
    Green S; Liu PY; O'Sullivan J
    J Clin Oncol; 2002 Aug; 20(16):3424-30. PubMed ID: 12177102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Power considerations for testing an interaction in a 2 x k factorial design with a failure time outcome.
    Xiang AH; Sather HN; Azen SP
    Control Clin Trials; 1994 Dec; 15(6):489-502. PubMed ID: 7851110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The detection of gene-environment interaction for continuous traits: should we deal with measurement error by bigger studies or better measurement?
    Wong MY; Day NE; Luan JA; Chan KP; Wareham NJ
    Int J Epidemiol; 2003 Feb; 32(1):51-7. PubMed ID: 12690008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Test for the consistency of noninferiority from multiple clinical trials.
    Yan X; Wang MC; Su X
    J Biopharm Stat; 2007; 17(2):265-78. PubMed ID: 17365223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, analysis and presentation of factorial randomised controlled trials.
    Montgomery AA; Peters TJ; Little P
    BMC Med Res Methodol; 2003 Nov; 3():26. PubMed ID: 14633287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterogeneity of stroke pathophysiology and neuroprotective clinical trial design.
    Muir KW
    Stroke; 2002 Jun; 33(6):1545-50. PubMed ID: 12052989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects.
    Benedetti F; Carlino E; Piedimonte A
    Lancet Neurol; 2016 Jun; 15(7):736-747. PubMed ID: 27106073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial.
    Lee IM; Cook NR; Gaziano JM; Gordon D; Ridker PM; Manson JE; Hennekens CH; Buring JE
    JAMA; 2005 Jul; 294(1):56-65. PubMed ID: 15998891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample Size Requirements and Study Duration for Testing Main Effects and Interactions in Completely Randomized Factorial Designs When Time to Event is the Outcome.
    Moser BK; Halabi S
    Commun Stat Theory Methods; 2015; 44(2):275-285. PubMed ID: 25530661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two-by-Two Factorial Cancer Treatment Trials: Is Sufficient Attention Being Paid to Possible Interactions?
    Freidlin B; Korn EL
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Problems and challenges in the design of irritable bowel syndrome clinical trials: experience from published trials.
    Spiller RC
    Am J Med; 1999 Nov; 107(5A):91S-97S. PubMed ID: 10588179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.